Abbvie Inc. Common Stock (ABBV) 55.01 $ABBV
Stock Market Today: Markets Pop as Fed Alludes to End of Stimulus
at The Street - Wed Jul 09, 3:58PM CDT
Markets gained ground on Wednesday following the release of Federal Open Market Committee minutes.
Insys Completes Study on Dronabinol Oral Solution - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 3:55PM CDT
Insys Therapeutics, Inc. (INSY) announced that it has successfully completed a human abuse study on dronabinol oral solution, a liquid formulation of the synthetic cannabinoid dronabinol.
AbbVie Boosts Offer for UK-Based Shire Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 3:30PM CDT
AbbVie Inc. (ABBV) continues to pursue Shire (SHPG) and has now come up with a fourth proposal.
AbbVie Retracts CEO Claims of Shire Bid Support
at The Street - Wed Jul 09, 12:00PM CDT
AbbVie backed down from a claim underpinning its sweetened $52 billion offer for Irish drugmaker Shire after Takeover Panel intervention.
Stock Market Today: U.S. Stocks Advance Ahead of Fed Minutes; Alcoa Rises
at The Street - Wed Jul 09, 11:10AM CDT
U.S. benchmark stock indices are looking up Wednesday after aluminum giant Alcoa kicked off the second-quarter earnings season with better-than-expected results.
Celgene Drug Otezla Fails Trial, But Street Sanguine
at Investor's Business Daily - Wed Jul 09, 10:52AM CDT
Big-cap biotech Celgene (CELG) reported Wednesday that its drug Otezla failed a trial for an inflammatory spinal disease, but the stock rebounded from an early drop as analysts said the news wasn't a surprise. The phase three study looked at Otezla...
Why AbbVie (ABBV) Stock Is Slipping This Morning
at The Street - Wed Jul 09, 10:04AM CDT
The drugmaker was forced to retract comments by its CEO about shareholder support for its $51 billion bid for Shire (SHPG) after being caught by British takeover rules.
Drugmakers and Dublin
Chris Hill and Bill Barker, The Motley Fool - Motley Fool - Wed Jul 09, 8:30AM CDT
On Tuesday's Market Foolery, host Chris Hill and Bill Barker, a Motley Fool Funds analyst, jump into the murky waters of AbbVie 's latest bid for Shire . American pharmaceutical firm AbbVie has increased its bid for Shire, a drugmaker based in...
Biotech Stock Roundup: Regado Plunges on Study Update, Jazz Gains on Product Acquisition Deal - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 09, 8:15AM CDT
Regado was a big loser last week with the company announcing that an unplanned data review by a Data Safety Monitoring Board (DSMB) is being conducted for a late-stage study on lead pipeline candidate.
Wednesday’s Top Biotech Stories: Celgene, AbbVie, Shire, and Sanofi
Leo Sun, The Motley Fool - Motley Fool - Wed Jul 09, 7:58AM CDT
Let's take a quick look at four stocks -- Celgene , AbbVie , Shire , and Sanofi -- which could all loom large in biotech headlines this Wednesday morning. Celgene's Otezla fails a late-stage trial Celgene has just announced that Otezla,...
Stock Market Today: Stock Futures Rise Ahead of Fed Minutes; Alcoa Advances
at The Street - Wed Jul 09, 7:45AM CDT
Stock futures are ticking higher Wednesday after aluminum giant Alcoa books better-than-expected results. The markets also await the latest Fed minutes.
Ahead of the Bell: Salix Pharma to buy Cosmo Tech
By The Associated Press - AP - Wed Jul 09, 7:37AM CDT
Shares of Salix Pharmaceuticals fell Wednesday before markets opened and a day after it announced plans to become the latest U.S. company to incorporate overseas and lower its taxes.
July 9 Premarket Briefing: 10 Things You Should Know
at The Street - Wed Jul 09, 5:52AM CDT
U.S. stock futures rise slightly ahead of Fed minutes; Citigroup and Justice Department close to a deal; Amazon offers Hachette authors a deal.
European Stocks Slide Ahead of Fed Minutes
at The Street - Wed Jul 09, 4:54AM CDT
Global stock indices on Wednesday extend steep losses from the previous session.
AbbVie raises its bid for Shire
at Investor's Business Daily - Tue Jul 08, 5:47PM CDT
The U.S. pharma raised its offer for U.K. drugmaker Shire (SHPG) by 11%, or 22.44 British pounds and 0.8568 AbbVie (ABBV) share for each share of Shire, to more than $51 bil. It's AbbVie's 4th attempt at a buyout after Shire said that the earlier...
If AbbVie Buys Shire, Dividend Investors Should Cheer
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 08, 4:01PM CDT
AbbVie has made another offer to acquire Shire in a bid to offset looming patent risk and lower its tax rate. Since Shire is generating a significant amount of free cash and currently doesn't pay much in the way of a dividend, acquiring the...
Major Indexes Cut More Losses; Alcoa Turns Up Ahead Of Earnings
at Investor's Business Daily - Tue Jul 08, 1:57PM CDT
Stocks shook off more losses but were still on pace to finish lower for a second straight session. The Nasdaq was off by 1.3%, while the Dow Jones industrial average and the S&P 500 were each off by 0.6%. Turnover continued to track sharply higher on...
Is This Johnson & Johnson's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 1:00PM CDT
Johnson & Johnson has been one of the top-performing Dow stocks of 2014, rising nearly 18% year to date. J&J's performance has been driven primarily by stellar top-line growth in its pharmaceutical division, where year-over-year sales...
AbbVie Ups the Stakes in Its Attempt to Acquire Shire
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 08, 12:20PM CDT
Global pharmaceutical giant AbbVie , perhaps best-known for producing the current best-selling drug in the world, arthritis treatment Humira, outlined a new proposal this morning that would boost its previous offer price to purchase Irish...
Novartis' CTL109 Gets Breakthrough Therapy Designation from the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 11:00AM CDT
Novartis (NVS) announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, CTL019.
Stock Market Today: Markets Pop as Fed Alludes to End of Stimulus
at The Street - Wed Jul 09, 3:58PM CDT
Markets gained ground on Wednesday following the release of Federal Open Market Committee minutes.
Insys Completes Study on Dronabinol Oral Solution - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 3:55PM CDT
Insys Therapeutics, Inc. (INSY) announced that it has successfully completed a human abuse study on dronabinol oral solution, a liquid formulation of the synthetic cannabinoid dronabinol.
AbbVie Boosts Offer for UK-Based Shire Pharma - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jul 09, 3:30PM CDT
AbbVie Inc. (ABBV) continues to pursue Shire (SHPG) and has now come up with a fourth proposal.
AbbVie Retracts CEO Claims of Shire Bid Support
at The Street - Wed Jul 09, 12:00PM CDT
AbbVie backed down from a claim underpinning its sweetened $52 billion offer for Irish drugmaker Shire after Takeover Panel intervention.
Stock Market Today: U.S. Stocks Advance Ahead of Fed Minutes; Alcoa Rises
at The Street - Wed Jul 09, 11:10AM CDT
U.S. benchmark stock indices are looking up Wednesday after aluminum giant Alcoa kicked off the second-quarter earnings season with better-than-expected results.
Celgene Drug Otezla Fails Trial, But Street Sanguine
at Investor's Business Daily - Wed Jul 09, 10:52AM CDT
Big-cap biotech Celgene (CELG) reported Wednesday that its drug Otezla failed a trial for an inflammatory spinal disease, but the stock rebounded from an early drop as analysts said the news wasn't a surprise. The phase three study looked at Otezla...
Why AbbVie (ABBV) Stock Is Slipping This Morning
at The Street - Wed Jul 09, 10:04AM CDT
The drugmaker was forced to retract comments by its CEO about shareholder support for its $51 billion bid for Shire (SHPG) after being caught by British takeover rules.
Drugmakers and Dublin
Chris Hill and Bill Barker, The Motley Fool - Motley Fool - Wed Jul 09, 8:30AM CDT
On Tuesday's Market Foolery, host Chris Hill and Bill Barker, a Motley Fool Funds analyst, jump into the murky waters of AbbVie 's latest bid for Shire . American pharmaceutical firm AbbVie has increased its bid for Shire, a drugmaker based in...
Biotech Stock Roundup: Regado Plunges on Study Update, Jazz Gains on Product Acquisition Deal - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Jul 09, 8:15AM CDT
Regado was a big loser last week with the company announcing that an unplanned data review by a Data Safety Monitoring Board (DSMB) is being conducted for a late-stage study on lead pipeline candidate.
Wednesday’s Top Biotech Stories: Celgene, AbbVie, Shire, and Sanofi
Leo Sun, The Motley Fool - Motley Fool - Wed Jul 09, 7:58AM CDT
Let's take a quick look at four stocks -- Celgene , AbbVie , Shire , and Sanofi -- which could all loom large in biotech headlines this Wednesday morning. Celgene's Otezla fails a late-stage trial Celgene has just announced that Otezla,...
Stock Market Today: Stock Futures Rise Ahead of Fed Minutes; Alcoa Advances
at The Street - Wed Jul 09, 7:45AM CDT
Stock futures are ticking higher Wednesday after aluminum giant Alcoa books better-than-expected results. The markets also await the latest Fed minutes.
Ahead of the Bell: Salix Pharma to buy Cosmo Tech
By The Associated Press - AP - Wed Jul 09, 7:37AM CDT
Shares of Salix Pharmaceuticals fell Wednesday before markets opened and a day after it announced plans to become the latest U.S. company to incorporate overseas and lower its taxes.
July 9 Premarket Briefing: 10 Things You Should Know
at The Street - Wed Jul 09, 5:52AM CDT
U.S. stock futures rise slightly ahead of Fed minutes; Citigroup and Justice Department close to a deal; Amazon offers Hachette authors a deal.
European Stocks Slide Ahead of Fed Minutes
at The Street - Wed Jul 09, 4:54AM CDT
Global stock indices on Wednesday extend steep losses from the previous session.
AbbVie raises its bid for Shire
at Investor's Business Daily - Tue Jul 08, 5:47PM CDT
The U.S. pharma raised its offer for U.K. drugmaker Shire (SHPG) by 11%, or 22.44 British pounds and 0.8568 AbbVie (ABBV) share for each share of Shire, to more than $51 bil. It's AbbVie's 4th attempt at a buyout after Shire said that the earlier...
If AbbVie Buys Shire, Dividend Investors Should Cheer
Todd Campbell, The Motley Fool - Motley Fool - Tue Jul 08, 4:01PM CDT
AbbVie has made another offer to acquire Shire in a bid to offset looming patent risk and lower its tax rate. Since Shire is generating a significant amount of free cash and currently doesn't pay much in the way of a dividend, acquiring the...
Major Indexes Cut More Losses; Alcoa Turns Up Ahead Of Earnings
at Investor's Business Daily - Tue Jul 08, 1:57PM CDT
Stocks shook off more losses but were still on pace to finish lower for a second straight session. The Nasdaq was off by 1.3%, while the Dow Jones industrial average and the S&P 500 were each off by 0.6%. Turnover continued to track sharply higher on...
Is This Johnson & Johnson's Worst Nightmare?
George Budwell, The Motley Fool - Motley Fool - Tue Jul 08, 1:00PM CDT
Johnson & Johnson has been one of the top-performing Dow stocks of 2014, rising nearly 18% year to date. J&J's performance has been driven primarily by stellar top-line growth in its pharmaceutical division, where year-over-year sales...
AbbVie Ups the Stakes in Its Attempt to Acquire Shire
Sean Williams, The Motley Fool - Motley Fool - Tue Jul 08, 12:20PM CDT
Global pharmaceutical giant AbbVie , perhaps best-known for producing the current best-selling drug in the world, arthritis treatment Humira, outlined a new proposal this morning that would boost its previous offer price to purchase Irish...
Novartis' CTL109 Gets Breakthrough Therapy Designation from the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jul 08, 11:00AM CDT
Novartis (NVS) announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, CTL019.
